Phase II Randomized Study of Continuing Treatment With Docetaxel Versus Switching to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in the First Line Treatment of Patients With Castration-Resistant Metastatic Prostate Cancer.

Trial Profile

Phase II Randomized Study of Continuing Treatment With Docetaxel Versus Switching to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in the First Line Treatment of Patients With Castration-Resistant Metastatic Prostate Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2013

At a glance

  • Drugs Cabazitaxel (Primary) ; Docetaxel
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SWITCH
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Sep 2012 Planned End Date changed from 1 Sep 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top